$599

Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other

August 20, 2024

Tirzepatide Three-Year Positive Pre-Diabetes and Weight-Loss Results; Medtronic CY Q2 ’24 (FY Q1 ’25) Earnings Update; Tandem iOS app update; August 19-22 CHMP Agenda

A series of cardiometabolic-related news items have been observed from Lilly, Medtronic, Tandem, and EMEA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Return to Home